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Antidepressant medications and psychotherapies, especially
cognitive–behavioural therapy (CBT), constitute two major
options as empirically supported treatments for adults with major
depression.1,2 Psychotherapies have traditionally been believed to
be better suited for treating people with mild depression. For
example, the third edition of the practice guidelines for major
depression published by the American Psychiatric Association
states: ‘Use of a depression-focused psychotherapy alone is
recommended as an initial treatment choice for patients with mild
to moderate major depressive disorder’. However, controversies
have arisen recently with regard to the influence of baseline
severity on the efficacy of psychotherapies for depression. One
study-level analysis of trials comparing various psychotherapies,
including CBT, interpersonal psychotherapy and supportive
therapy, against pill placebo did not find an association between
the study’s effect size and mean baseline depression severity.3 Yet
another analysis at the study level found no effect of pre-treatment
depression scores on the effect size of different psychotherapies
over various control conditions (including waiting list, no
treatment or pill placebo), but did find a clear indication that
the effect size was bigger and statistically significant in high-
severity patients and smaller and non-significant in low-severity
patients in the small subset of studies that had examined such
differences within each study.4 However, these study-level analyses
are limited in statistical power and are subject to the ecological
fallacy that the relationships observed at the group level may
not reflect the true relationships at the individual level.5 Meta-
analyses based on individual-participant data (IPD-MA) are
necessary to examine patient-level effect moderators, including
baseline severity. An IPD-MA of low-intensity psychotherapies
(such as guided self-help bibliotherapy and internet-delivered
therapy: 16 randomised controlled trails (RCTs), 2470 patients)
found a significant albeit small interaction between baseline
severity and treatment effect, suggesting that patients who are
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Background
The influence of baseline severity has been examined for
antidepressant medications but has not been studied
properly for cognitive–behavioural therapy (CBT) in
comparison with pill placebo.
Aims
To synthesise evidence regarding the influence of initial
severity on efficacy of CBT from all randomised controlled
trials (RCTs) in which CBT, in face-to-face individual or group
format, was compared with pill-placebo control in adults with
major depression.
Method
A systematic review and an individual-participant data
meta-analysis using mixed models that included trial effects
as random effects. We used multiple imputation to handle
missing data.
Results
We identified five RCTs, and we were given access to
individual-level data (n= 509) for all five. The analyses
revealed that the difference in changes in Hamilton Rating
Scale for Depression between CBT and pill placebo was not
influenced by baseline severity (interaction P= 0.43).
Removing the non-significant interaction term from the
model, the difference between CBT and pill placebo was a
standardised mean difference of 70.22 (95% CI 70.42 to
70.02, P= 0.03, I2 = 0%).
Conclusions
Patients suffering from major depression can expect as
much benefit from CBT across the wide range of baseline
severity. This finding can help inform individualised treatment
decisions by patients and their clinicians.
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initially more depressed demonstrate slightly larger treatment
effects with such low-intensity interventions.6
Given the direct relevance of baseline severity with respect to
tailoring treatment and informed consent for patients with mild,
moderate and severe symptoms, the possibility of the influence
of baseline severity on efficacy of treatments for adults with major
depression merits further investigation. Such investigation needs
to be methodologically rigorous in applying individual-
participant-level meta-analysis and procedurally comprehensive
in identifying and assembling individual data to be so analysed.
The current study aims to systematically identify all RCTs
examining CBT in a face-to-face format in comparison with pill
placebo in the treatment of adults with major depression, retrieve
their individual-level data and apply IPD-MA to examine the
possible influence of baseline depression severity on its efficacy.
CBT is by far the best-researched and widely practised form of
psychotherapy for depression.7,8 We chose pill placebo as the
control condition in this IPD-MA mainly for two reasons. First,
traditional control conditions used in psychotherapy trials, such
as waiting list, no treatment or treatment as usual, are too
heterogeneous and may be affected by publication bias.9,10
Second, and more importantly, the pill-placebo condition will
control for non-specific placebo effects including expectation,
attention and support and will offer a common comparison
condition for both antidepressants and psychotherapies. Our
hypothesis was that increases in baseline severity would be
associated with increases in the advantages of CBT over pill
placebo among adult patients with major depression.
Method
Selection of studies and data extraction
The eligibility criteria for the present IPD-MA were as follows:
(a) RCT;
(b) the participants were adult patients with major depressive
disorder, diagnosed according to any operational diagnostic
criteria including the Research Diagnostic Criteria, DSM-III,
DSM-III-R, DSM-IV, DSM-5 or ICD-10;
(c) the intervention was face-to-face CBT in individual or group
format. We defined CBT as a psychotherapy focused on the
impact of a patient’s dysfunctional thoughts on his/her
current behaviour and future functioning and aimed at
evaluating, challenging and modifying such dysfunctional
beliefs (cognitive restructuring). We included two subtypes
thereof, namely one in which cognitive restructuring is the
core element and one in which it is an important component
but in which at least two other components such as behavioural
activation, social skills training, relaxation or coping skills also
have a prominent role;11
(d) the non-specific control was pill placebo. The trial could have
other active or non-active intervention arms.
We conducted a systematic and cumulative search of all
RCTs of psychotherapies for depression (www.evidencebased
psychotherapies.org). The searches included PubMed, PsycInfo,
EMBASE and the Cochrane Central Register of Controlled Trials
using keywords indicative of psychological treatment and
depression, and were supplemented by examination of published
meta-analyses of psychological treatments for depression, up to
January 2014. An updated search was conducted on 16 January
2015 with PubMed and the Cochrane Central Register. We
identified the relevant studies satisfying our eligibility criteria
from this database and then asked the primary authors of all
the identified studies to contribute individual-participant data
for our primary and secondary outcomes (see below) as well as
any possible effect moderators that each study may have
measured. Study quality was assessed using four criteria from
the Cochrane Collaboration’s risk of bias tool for random
sequence generation, concealment of random allocation, masking
of assessors and complete outcome reporting. When the
information provided in the publications was not clear, we sought
information from the original study authors.
Outcomes
Our pre-specified primary outcome measure was change in the
Hamilton Rating Scale for Depression (HRSD)12 scores from
baseline to the last study time point at which valid comparison
between CBT and pill placebo could be made. Two studies
employed the pill-placebo arm only through week 8 of a 16-week
study,13,14 in which case we were able to compare CBT against pill
placebo up to that time point only. Our secondary outcome was
change in the Beck Depression Inventory (BDI).15
Analyses
We first verified the integrity of the individual-participant data by
comparing their descriptive statistics against the published figures.
We conducted IPD-MA to estimate the difference in symptom
change scores between the CBT and pill-placebo arms and to
examine the influence of the baseline symptom severity on this
difference. Because the original studies used different versions of
the HRSD and BDI with different item questions and with
different numbers of items, such continuous outcomes were
standardised within each study, that is, the individual patients’
raw scores at baseline and at end-point were divided by the
study-specific standard deviations of end-point scores. After this
standardisation of scores from different scales, when we
graphically presented the relationship between the scores at
baseline and the changes in scores, we subtracted the grand mean
of all the studies’ standardised scores from individual standardised
scores in order to anchor the horizontal and vertical axes in the
figure. The relationships between these standardised baseline
symptom severity scores and the differences in symptom change
scores were examined as the interaction term between baseline
severity and treatment in the mixed models. When this interaction
term was not statistically significant, we dropped the interaction
term and estimated the main effect of treatment. The mixed
models included trial effects as random effects throughout.
Missing data in HRSD and BDI scores were handled by the
multiple imputation method using study, treatment, age, gender,
minority status, marital status, employment, education, age at
onset, diagnosis of depression subtype, presence of previous
episodes, length of current episode, comorbid anxiety disorders,
past substance use disorders, length of treatment and HRSD or
BDI scores at baseline and at the last study time point as predictors.
Multiple imputation is one of the currently recommended
alternatives to the long-used last-observation-carried-forward
(LOCF) method.16 It has some advantages over hierarchical linear
modelling as well as LOCF because auxiliary variables that are not
included in the final analysis model can be used in the imputation
model.17
We also conducted sensitivity analyses (a) excluding studies
that continued the pill-placebo arm only through the mid-point
of acute treatment, (b) excluding studies that administered CBT
in a group format, (c) including patients diagnosed with
dysthymia or minor depression at baseline, (d) employing the
multiple imputation using the predictors other than treatment,
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All reported P-values are two-tailed and P50.05 was chosen
as the threshold for statistical significance. An academic
statistician (S.T.) conducted all statistical analyses using SAS
version 9.3. This study was conducted in accordance with
PRISMA and PRISMA-IPD guidelines.18
Results
Studies and participants
We found five RCTs that satisfied our eligibility criteria (online
Fig. DS1).13,14,19–21 One study21 included some patients with
minor depression or dysthymia: the latter patients were excluded
in our primary analyses but were included in a sensitivity analysis
to give a wider range of baseline severity. All the primary authors
and their collaborators agreed to contribute to the present study
by providing individual-level data for the primary and secondary
outcomes as well as possible effect moderators that they had
measured. The data from the NIMH Treatment of Depression
Collaborative Program19 were in the public domain and available
for inclusion.
Table 1 lists the characteristics of the five RCTs that compared
CBT against pill placebo. We obtained individual-patient data for
509 patients with major depression and 46 patients with minor
depression and dysthymia. The mean age of the patients with
major depression participating in these trials was in the 30s or
40s, with a preponderance of women. In addition to CBT and
pill-placebo arms, the comparison of interest in the present study,
all the studies had an antidepressant medication arm and three
studies also included a different psychotherapy from CBT. One
study21 used the original 17-item version of HRSD, one study20
the 21-item version, and the remaining three studies13,14,19
employed the modified HRSD with additional items for atypical
symptoms. Two studies19,20 used the original BDI and three
studies13,14,21 used the second version.
All the studies were rated at low risk of bias for random
sequence generation, allocation concealment, masking and
incomplete outcome reporting, except for one study whose risk
of bias was rated unclear as to allocation concealment but low
for all the other aspects.14 Raters masked to treatment assignment
administered the HRSD in all studies. As a self-report measure,
patients knew whether they were receiving CBT or were in a
‘medication’ condition when they completed the BDI; however,
they were masked as to whether they were taking an active
medication or a pill placebo.
Baseline severity and symptom change
in CBT and pill placebo
Figure 1 depicts observed and estimated changes in standardised
HRSD scores in the CBT or pill-placebo arms. The end-point
standard deviations used to standardise the HRSD score were
5.8 for DeRubeis et al,13 6.6 for Dimidjian et al,14 6.3 for Elkin
et al,19 6.2 for Hegerl et al 21 and 7.3 for Jarrett et al,20 and we used
the grand means of the standardised scores from all the studies,
3.2 for baseline scores and 1.3 for change scores, as subtrahends
in scaling the axes in Fig. 1. The individual participant-level
meta-analysis revealed that the differences in changes in HRSD
between CBT and pill-placebo arms were not influenced by
baseline HRSD severity. The slopes in the CBT and placebo arms
were estimated to be 70.615 (95% C1 70.839 to 70.392,
P50.01) and 70.526 (95% CI 70.733 to 70.319, P50.01),
respectively and the interaction term, i.e. the difference between
the slopes, was 70.089 (70.311 to 0.133, P= 0.43).
The interaction between baseline severity and treatment
condition was also not significant with change in BDI as the
dependent variable. The slopes in the CBT and pill-placebo arms
were estimated to be 70.541 (95% CI 70.724 to 70.358,
P50.01) and 70.615 (95% CI 70.793 to 70.438, P50.01),
respectively and the interaction term was 0.074 (70.175 to
0.323, P= 0.56). Removing the higher-order non-significant
interaction terms from the models, the IPD-MA revealed that the
standardised mean difference (SMD) between CBT and pill-placebo
arms was 70.220 (95% CI 70.419 to 70.022, P= 0.03, I 2 = 0%)
for the HRSD and 70.046 (95% CI 70.264 to 0.172, P= 0.68,
I 2 = 0%) for the BDI (Table 2).
Sensitivity analyses
We also conducted sensitivity analyses to examine the robustness
of our primary analyses by (a) excluding DeRubeis et al 13 and
Dimidjian et al’s14 studies that had the pill-placebo arm only up
to the mid-point of the study, (b) excluding Hegerl et al ’s study21
that administered group-format CBT, (c) including patients
diagnosed with dysthymia or minor depression at baseline, (d)
multiple imputation using the predictors other than treatment
and (e) restricting the sample to participants who completed
the treatment only (Table 3). The interaction terms were all
statistically non-significant. The treatment effects in models in
which the interaction term was excluded were statistically
significant in the sensitivity analyses (c) and (e) above but not
in (a), (b) or (d), likely because of reduced sample sizes or to
residual bias related to missing data. However, the estimated
effects ranged between 70.16 and 70.27, and in all instances
their 95% confidence intervals overlapped with those from the
primary analysis (70.22, 95% CI 70.42 to 70.02).
Discussion
Main findings
We identified five pill-placebo-controlled randomised studies of
CBT conducted to date, obtained their individual-level data
(509 patients with major depression), and conducted an IPD-
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Fig. 1 Observed (dots) and estimated (lines) changes in
standardised scores on Hamilton Rating Scale for Depression



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Initial severity of depression and efficacy of CBT
its efficacy. There was no statistically significant influence of base-
line depression severity, measured either with HRSD or BDI, on
subsequent differential symptom change between CBT and pill
placebo. The findings, thus, did not support our initial hypothesis
that the efficacy of CBT over pill placebo would increase as
baseline depression severity increased, when it was measured
either by patient report or clinician ratings.
Finding that baseline severity has little influence on the
efficacy of CBT can be said to be largely in accord with the
previous literature, using study-level data4,22 or individual-
participant data.6 Although a handful of studies that examined
subgroup differences between low- v. high-severity groups have
found evidence for moderation (with differences relative to pill
placebo emerging only among patients with more severe
depression) that was only the case for more purely behavioural
interventions or interpersonal psychotherapy.4 The IPD-MA that
did find moderation by baseline severity concluded that the
magnitude of interaction was small and that patients who were
less severely depressed could derive as much benefit from low-
intensity psychotherapies as did individuals who were more
severely depressed.6 Taken together, the evidence to date regarding
the comparison of CBT v. pill placebo suggests that we can expect
as much benefit from CBT across a wide range of baseline
depression severity.
Excluding the non-significant interaction term and compared
with pill placebo, CBT led to greater symptom reduction, on
average, by an SMD of 70.22 (95% CI 70.42 to 70.02,
P= 0.03) on HRSD. The SMD in terms of BDI was 70.05 and
was not statistically significant (95% CI 70.26 to 0.17,
P= 0.68). The HRSD was the prespecified primary outcome in this
IPD-MA, as it was in all the included studies.13,14,19–21 Generally,
observer-rating scales including HRSD are said to be more
sensitive to change than self-rating scales such as BDI.23,24
Specifically in all the included studies, the HRSD was rated by
assessors masked to all the treatments whereas the BDI was self-
rated by participants who were masked to the distinctions in
medications (active v. placebo) but not to those between CBT v.
medications. It must also be pointed out that BDI was more often
missing than HRSD in the original data-set (19.5% v. 13.7%).
Comparison with findings from other studies
The SMD of 0.22 found in the primary analysis of this meta-
analysis is smaller than the previously estimated SMD of CBT over
waiting-list conditions, the most common control condition in
the psychotherapy trials, such as 0.8225 or 0.85.8 However, it must
be remembered that the magnitude of effect is dependent not only
on the effects of treatment but also on the effects of the control
condition against which the therapy is compared. Waiting-list
control conditions are known to lead to greater effect estimates
than other control conditions, including clinical management that
is accompanied by the provision of medication placebos.10,23 In
the control arms in four of the five trials in our data-set13,14,19,20
the pharmacotherapists explicitly followed the clinical management
protocol originally developed for the NIMH Treatment of
Depression Collaborative Program24 and in the remaining study21
the psychiatrists’ practices were in accord with this protocol, so
that these pill-placebo conditions have included strong supportive
components. Furthermore, the effect size estimates obtained in
previous comparisons of psychotherapies with various control
conditions may have been inflated by the inclusion of poor-quality
studies26 and by publication bias.9 Our choice of the pill-placebo
condition, which controls for the non-specific effects of
expectation, attention and support, our comprehensive and
systematic search of the relevant literature, and the high quality
of the included studies including masked assessment of the
outcome should have mitigated these problems.
Second, our estimate of the CBT–pill-placebo difference was
also smaller than that reported in a previous study-level meta-
analysis of pill-placebo-controlled trials. Lynch et al 27 reported
an SMD of 0.41 (95% CI 0.21–0.61) between CBT and pill placebo
from a study-level aggregate data meta-analysis of four of the five
studies included in our IPD-MA.13,14,19,20 This meta-analysis took
effect size estimates for the included studies according to the
original publications (see Table 1). One of the estimates was based
on hierarchical linear modelling (HLM),13 two others on the
LOCF data19,20 (although results from random regression were
available from one20 but were not used), and another on
completers’ data.14 In the arms of the included studies, 15–64%
of the randomised patients dropped out per arm and therefore
5
Table 2 Treatment effects of cognitive–behavioural therapy (CBT) over pill placebo on different outcome measures
P for
interaction






Hamilton Rating Scale for Depression change 0.43 0.03 70.220 (70.419 to 70.022)
Beck Depression Inventory change 0.56 0.68 70.046 (70.264 to 0.172)
a. Estimated by random-effects models after multiple imputation without the interaction term.
Table 3 Sensitivity analyses
P for
interaction






Excluding two trials that continued the pill-placebo arm only through the
mid-point of acute treatment and in which the comparison between CBT
and placebo was therefore possible only up to the middle of the study13,14 0.21 0.12 70.217 (70.494 to 0.060)
Excluding a trial that administered CBT in group format21 and limiting to CBT
in individual format 0.67 0.08 70.191 (70.407 to 0.024)
Including minor depression and dysthymia 0.43 0.02 70.230 (70.431 to 70.030)
Multiple imputation using predictors other than treatment 0.34 0.13 70.158 (70.364 to 0.048)
Complete-case analysis 0.39 0.01 70.266 (70.480 to 70.053)
CBT, cognitive–behavioural therapy.
a. Estimated by random-effects models without the interaction term after multiple imputation except for the complete-case analysis.
Furukawa et al
did not provide data at the end-point assessment. How drop-out was
handled in the respective studies would be expected to influence
estimates of the CBT v. pill-placebo difference. Although in the
original publications, the trial authors may have used statistical
approaches, including HLM14,21 that are currently considered
appropriate or were deemed to be so at the time they were published,
the systematic review authors were obliged to extract data in the
format amenable to meta-analysis, as detailed above. However, as
methods have progressed today, neither the LOCF nor the completers’
data would be considered the standard method to summarise and
analyse data with missing values.16 By contrast, we were able to
meta-analyse the five studies with individual-participant data, which
allowed us to use multiple imputation and test for effects using a
mixed model. It is increasingly recognised that IPD-MA has many
advantages, albeit with its own difficulties,28 and some authors
consider it to be the gold standard in evidence synthesis.29
Many questions remain when we try to factor antidepressant
pharmacotherapy into the comparison between CBT and pill
placebo. First, our estimated standardised effect size of 0.22
appears smaller than the publication-bias-free estimate of 0.31
of newer antidepressants over pill placebo.30 However, it is
problematic to compare these estimates directly with each other,
as they were obtained from different original investigations.
Moreover, our estimate for CBT v. pill-placebo difference is based
on IPD-MA using multiple imputation, whereas that of the
antidepressant v. pill-placebo difference derives from an aggregate
data meta-analysis from published and unpublished trials, many
of which used LOCF. Second, when directly compared in a
study-level meta-analysis, the difference between CBT and
second-generation antidepressants was not statistically significant.31
A recent study applying IPD-MA to 1466 patients from 14 out of 24
identified relevant studies comparing CBT and pharmacotherapies
revealed a small difference in effect size (SMD = 0.11, P= 0.03)
but no significant differences in response or remission rates (odds
ratio (OR) = 1.24, P= 0.12 and OR = 1.18, P= 0.22, respectively).32
Lastly, the independence of the effect of CBT for depression from
the baseline severity, as shown in the present analysis, is also in
contrast to some claims to the contrary with regard to the effect
of antidepressant drugs.33 There is collateral evidence that the effect
of antipsychotic drugs is also moderated by baseline psychotic
severity.34 However, the question of the influence of baseline
symptom severity on antidepressant medications’ efficacy is hardly
closed,35 and hence neither is the issue if such influences may
differ between antidepressant medication and psychotherapies.
Limitations
Our study has limitations. First, detection of an interaction effect
requires a large sample size. The present findings require
replication with a larger sample of trials designed to test the
interaction. The trials from which the data were extracted were
not designed to test this hypothesis, but do provide a ‘first look’
into this question using all available data. Given the wide
confidence interval around zero for the interaction coefficient in
the present study, it is possible that our finding represents a type
II error. Although none of the sensitivity analyses were suggestive
of possible interaction effects, future studies may nonetheless still
reveal an interaction that we failed to detect in the data available
to us. It is disappointing that there were only 5 studies that
compared CBT with pill placebo, whereas more than 20 studies
compared it with antidepressant medications32 and hundreds of
studies have compared antidepressants with pill placebo.36 Second,
we were not able to examine important potential moderators such
as therapist competence or other patient characteristics including
comorbid personality disorder because such data were not
consistently available in the obtained data-set although such
covariates were requested in the source data from parent trials.
Third, as the included studies used different versions of HRSD
or BDI, we were obliged to standardise these severity measures
using their means and standard deviations. This was unavoidable
in order to synthesise different metrics across studies. Lastly, in
combining data, we also ignored some design features from the
parent studies that may or may not prove to be important in
future understanding of antidepressant treatment effects (for
example exclusive focus on subtypes of major depression in some
studies, such as atypical depression,20 primary care settings;21
inclusion of a ‘non-specific treatment run-in’ prior to random-
isation;19,20 differential lengths of acute phase treatment; or
inclusion of active psychotherapy arms other than CBT in the
study). In view of today’s growing emphasis on the importance
of the totality of evidence37 and hence systematic reviews
including IPD-MAs,29 researchers may benefit by making
concerted efforts to measure core variables in their original
research and then by contributing to the common database.38
Implications
Clinical implications of the present study may be as follows. First
of all, patients and their clinicians can expect as much benefit
from CBT for major depression across its wide range of baseline
severity from mild through severe. Second, the benefit that can
be expected was an effect size of 0.22, from which it can be
calculated that the number needed to treat (NNT) is 12 for typical
cases of major depression, for whom the expected placebo response
rates may be between 30 and 50%.39 This would compare favourably
with the NNT of nine that can be expected for antidepressants with
an effect size of 0.31 over placebo.30 The difference in NNTs to
obtain one more response with CBT or antidepressant medications
than with pill placebo is therefore small enough to allow value
judgements and preferences of individual patients to play a major
role in treatment decision-making.
There are several research implications. We have been fortunate
in having been able to identify and assemble all the relevant
randomised evidence on the topic. We need to foster further
collaborations in the field of psychotherapy research. Similar
collaboration is burgeoning and is welcome in all fields of medi-
cine.38 It is also expected that such collaboration after completion
of individual studies will increase the research community’s aware-
ness of the need for greater collaboration before individual studies
by agreeing on common core variables to be assessed in the studies.
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